A 2-year Study to Evaluate the Onset of Action of Cladribine Tablets in Subjects with Highly Active Relapsing Multiple Sclerosis: Results from MAGNIFY- MS Baseline Analysis

被引：0
|
作者：
De Stefano, N. [1 ]
Achiron, A. [2 ]
Barkhof, F. [3 ]
Chan, A. [4 ]
Derfuss, T. [5 ]
Hodgkinson, S. [6 ]
Leocani, L. [7 ]
Montalbant, X. [8 ]
Pratt, A. [9 ]
Schmierer, K. [10 ]
Sellebjerg, F. [11 ]
Vermersch, P. [12 ]
Wiendl, H. [13 ]
Keller, B. [14 ]
Roy, S. [15 ]
机构：
[1] Univ Siena, Dept Neurol & Behav Sci, Siena, Italy
[2] Sheba Acad Med Ctr, Multiple Sclerosis Ctr, Ramat Gan, Israel
[3] Vrije Univ Amsterdam Med Ctr, Dept Radiol, Amsterdam, Netherlands
[4] Univ Bern, Univ Hosp Berne, Bern, Switzerland
[5] Univ Hosp Basel, Dept Neurol, Basel, Switzerland
[6] Univ New South Wales Med, Ingham Inst Appl Med Res, Sydney, NSW, Australia
[7] Univ Vita Salute San Raffaele, Expt Neurophysiol Unit, Milan, Italy
[8] Univ Toronto, St Michaels Hosp, Toronto, ON, Canada
[9] Univ Montreal, Dept Neurosci, Montreal, PQ, Canada
[10] Queen Mary Univ London, Blizard Inst Neurosci, Barts & London Sch Med & Dent, London, England
[11] Univ Copenhagen, Rigshosp, Danish MS Ctr, Copenhagen, Denmark
[12] Univ Lille, INSERM, U1172, FHU Imminent,CHU Lille, Lille, France
[13] Univ Munster, Dept Neurol, Inst Translat Neurol, Munster, Germany
[14] Merck KGaA, Darmstadt, Germany
[15] Merck, Aubonne, Switzerland
来源：
EUROPEAN JOURNAL OF NEUROLOGY | 2020年 / 27卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
EPO1262
引用
收藏
页码：685 / 686
页数：2
相关论文
共 50 条
  • [41] Effect of daclizumab HYP treatment in highly active relapsing-remitting multiple sclerosis: results from the SELECT study
    Giovannoni, G.
    Radue, E. W.
    Havrdova, E.
    Riester, K.
    Greenberg, S.
    Glyman, S.
    Elkins, J.
    MULTIPLE SCLEROSIS JOURNAL, 2012, 18 : 189 - 189
  • [42] Long-term Efficacy of Cladribine Tablets in Patients with Relapsing-Remitting or Secondary Progressive Multiple Sclerosis: Analysis of Real World Data From the Italian Multiple Sclerosis Registry (CLARINET-MS)
    Patti, Francesco
    Visconti, Andrea
    Capacchione, Antonio
    Trojano, Maria
    NEUROLOGY, 2020, 94 (15)
  • [43] Retrospective data analysis of a German cohort of patients with active relapsing multiple sclerosis switching from anti-CD20 therapies to cladribine tablets and vice versa
    Konen, Franz Felix
    Pfeuffer, Steffen
    Jendretzky, Konstantin Fritz
    Gehring, Klaus
    Elias-Hamp, Birte
    Suehs, Kurt-Wolfram
    Pawlitzki, Marc
    Meuth, Sven
    Kleinschnitz, Christoph
    Pul, Refik
    Skripuletz, Thomas
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 328 - 330
  • [44] The Real-World Efficacy of Cladribine Tablets and Treatment Persistence in People with Highly Active Relapsing Multiple Sclerosis in Finland - A Follow-up Study After Four Years of Observation
    Rauma, Ilkka
    Viitala, Matias
    Soilu-Hanninen, Merja
    Atula, Sari
    Laakso, Sini
    Kuusisto, Hanna
    Niiranen, Marja
    Ryytty, Mervi
    Manni, Visa
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 386 - 387
  • [45] Baseline characteristics and interim analysis results of TRANSITION: a 2-year observational study evaluating the safety profile of patients with multiple sclerosis who switched from natalizumab to fingolimod
    Butzkueven, H.
    Weller, B.
    Giacomini, P. S.
    Cohan, S.
    Ziemssen, T.
    Tomic, D.
    Di Cantogno, E. Verdun
    Faivre, T.
    Sett, T.
    Trojano, M.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 283 - 284
  • [46] Safety of cladribine tablets for relapsing-remitting multiple sclerosis in patients with high disease activity: results from the phase III, 96-week CLARITY study
    Rammohan, K.
    Comi, G.
    Cook, S.
    Giovannoni, G.
    Rieckmann, P.
    Sorensen, P. Soelberg
    Vermersch, P.
    Kurukulasuriya, N.
    Bischof, D.
    Chang, P.
    Greenberg, S.
    JOURNAL OF NEUROLOGY, 2011, 258 : 259 - 259
  • [47] Efficacy of cladribine tablets for relapsing-remitting multiple sclerosis in patients with high disease activity: results from the phase III, 96-week CLARITY study
    Rammohan, K.
    Comi, G.
    Cook, S.
    Giovannoni, G.
    Rieckmann, P.
    Sorensen, P. Soelberg
    Vermersch, P.
    Kurukulasuriya, N.
    Chang, P.
    Greenberg, S.
    JOURNAL OF NEUROLOGY, 2011, 258 : 21 - 21
  • [48] Time to Qualifying Relapse by Previous Disease Modifying Therapy Status in Patients with Relapsing Multiple Sclerosis Treated with Cladribine Tablets over 2 Years in the CLARIFY-MS Study
    Patti, Francesco
    Brochet, Bruno
    Havrdova, Eva Kubala
    Solari, Alessandra
    Hupperts, R. M. M.
    Langdon, Dawn
    Lechner-Scott, Jeannette
    Piehl, Fredrik
    Selmaj, Krzysztof
    Smyk, Andrzej
    Lehn, Annette
    Montalban, Xavier
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 747 - 748
  • [49] Reduction in Healthcare and Societal Resource Utilization Associated with Cladribine Tablets in Patients with Relapsing-Remitting Multiple Sclerosis Analysis of Economic Data from the CLARITY Study
    Ali, Shehzad
    Paracha, Noman
    Cook, Stuart
    Giovannoni, Gavin
    Comi, Giancarlo
    Rammohan, Kottil
    Rieckmann, Peter
    Sorensen, Per Soelberg
    Vermersch, Patrick
    Greenberg, Steven
    Scott, David A.
    Joyeux, Alexandre
    CLINICAL DRUG INVESTIGATION, 2012, 32 (01) : 15 - 27
  • [50] Efficacy of Daclizumab HYP Treatment in Patients with Highly Active Relapsing-Remitting Multiple Sclerosis: Results from the SELECT Study
    Mehta, Lahar
    Giovannoni, Gavin
    Radue, Ernst-Wilhelm
    Havrdova, Eva
    Riester, Katherine
    Greenberg, Steven
    Elkins, Jacob
    NEUROLOGY, 2013, 80
12345